Calliditas announces supportive interim data from Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib.
In: ENP Newswire, 2023-07-14
Zeitungsartikel
Zugriff:
Titel: |
Calliditas announces supportive interim data from Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib.
|
---|---|
Link: | |
Zeitschrift: | ENP Newswire, 2023-07-14 |
Veröffentlichung: | 2023 |
Medientyp: | Zeitungsartikel |
Sonstiges: |
|